Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
4-(4-Nitro-phen-yl)morpholine.
Wang LJ, Li WW, Yang SY, Yang L. Wang LJ, et al. Acta Crystallogr Sect E Struct Rep Online. 2012 Apr 1;68(Pt 4):o1235. doi: 10.1107/S1600536812012172. Epub 2012 Mar 31. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 22606168 Free PMC article.
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY. Li WW, et al. Among authors: wang lj, wang xy, wang zr. J Med Chem. 2012 Apr 26;55(8):3852-66. doi: 10.1021/jm300042x. Epub 2012 Apr 6. J Med Chem. 2012. PMID: 22452518
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, Ji P, Zhang CH, Wang WJ, Lin XD, Li LL, Wei YQ, Yang SY. Yang J, et al. Among authors: wang lj, wang wj. J Med Chem. 2012 Dec 13;55(23):10685-99. doi: 10.1021/jm301365e. Epub 2012 Nov 16. J Med Chem. 2012. PMID: 23116168
Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model.
Li GB, Ma S, Yang LL, Ji S, Fang Z, Zhang G, Wang LJ, Zhong JM, Xiong Y, Wang JH, Huang SZ, Li LL, Xiang R, Niu D, Chen YC, Yang SY. Li GB, et al. Among authors: wang lj, wang jh. J Med Chem. 2016 Sep 22;59(18):8293-305. doi: 10.1021/acs.jmedchem.6b00604. Epub 2016 Sep 2. J Med Chem. 2016. PMID: 27535613
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY. Yang LL, et al. Among authors: wang lj. J Med Chem. 2013 Feb 28;56(4):1641-55. doi: 10.1021/jm301537p. Epub 2013 Feb 19. J Med Chem. 2013. PMID: 23362959
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, Wang L, Zhong L, Yang HY, Wang BL, Yu Y, Liu J, Cao Z, Wang X, Ji P, Wang Z, Chen X, Zhang S, Wei YQ, Yang SY. Pan Y, et al. Mol Cancer Ther. 2012 Apr;11(4):952-62. doi: 10.1158/1535-7163.MCT-11-0679. Epub 2012 Feb 8. Mol Cancer Ther. 2012. PMID: 22319204
Inflammation Triggers Chondrocyte Ferroptosis in TMJOA via HIF-1α/TFRC.
Chen BY, Pathak JL, Lin HY, Guo WQ, Chen WJ, Luo G, Wang LJ, Sun XF, Ding Y, Li J, Diekwisch TGH, Liu C. Chen BY, et al. Among authors: wang lj. J Dent Res. 2024 May 20:220345241242389. doi: 10.1177/00220345241242389. Online ahead of print. J Dent Res. 2024. PMID: 38766865
2,417 results